Concord Biotech Share Price | Concord Biotech Stock Screener
CONCORDBIO
Pharmaceuticals
Share Price NSE
₹1099.60
▼
-39.20 (-3.44%)
Share Price BSE
₹1099.40
▼
-39.55 (-3.47%)
As of May 27, 2026, the Concord Biotech share price (NSE: CONCORDBIO) is ₹1,099.60 on NSE and ₹1,099.40 on BSE, down 3.44% from the previous close, with shares trading between ₹1,096.20 and ₹1,145.50, and a 52-week range of ₹1,014.80–₹2,130.40.
Check CONCORDBIO 52-week high low for the annual price range and momentum.
Use the Concord Biotech stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Concord Biotech Market Cap
₹11,877.08 Cr.
CONCORDBIO P/E Ratio (TTM)
38.31
Concord Biotech P/B Ratio
6.52
EPS (TTM)
₹35.52
Dividend Yield
0.77%
Debt to Equity
-
CONCORDBIO 52 Week High
₹2130.40
Concord Biotech 52 Week Low
₹1014.80
Operating Margin
34.00%
Profit Margin
22.22%
CONCORDBIO Revenue (TTM)
₹288.00
EBITDA
₹105.00
Net Income
₹64.00
Total Assets
₹2,034.00
Total Equity
₹1,813.00
Concord Biotech Share Price Chart
Screen Concord Biotech share price with an interactive chart. Analyse CONCORDBIO price trends and volatility across different timeframes.
Concord Biotech Company Profile - Fundamental Screener
Screen Concord Biotech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for CONCORDBIO shares.
Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
SUDHIR JAIRAM VAID
ISIN
INE338H01029
Website
https://www.concordbiotech.com
Concord Biotech Balance Sheet Screener
Screen CONCORDBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 2,034 | 1,701 | 1,514 | 1,313 | 1,183 | 941 |
| Current Assets | 1,135 | 896 | 728 | 633 | 607 | 539 |
| Fixed Assets | 795 | 575 | 593 | 573 | 546 | 240 |
| Liabilities | ||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 38 | 32 | 32 | 54 | 77 | 55 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 1,813 | 1,527 | 1,290 | 1,103 | 999 | 770 |
| Share Capital | 11 | 11 | 11 | 10 | 10 | 10 |
| Reserves & Surplus | 1,802 | 1,516 | 1,280 | 1,094 | 990 | 761 |
Concord Biotech Income Statement Screener - Profit & Revenue Analysis
Screen Concord Biotech income statement and profit fundamentals.
Analyze CONCORDBIO quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Concord Biotech share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 288 | 263 | 219 | 439 | 261 | 320 | 228 | 330 | 252 | 271 | 208 | 285 | 250 | 165 | 195 |
| Expenses | 183 | 159 | 143 | 241 | 146 | 177 | 135 | 187 | 135 | 147 | 123 | 146 | 131 | 122 | 116 |
| EBITDA | 105 | 104 | 77 | 198 | 115 | 144 | 93 | 143 | 117 | 124 | 85 | 139 | 119 | 44 | 79 |
| Operating Profit % | 34.00% | 36.00% | 30.00% | 44.00% | 40.00% | 43.00% | 38.00% | 41.00% | 44.00% | 44.00% | 37.00% | 47.00% | 46.00% | 24.00% | 36.00% |
| Depreciation | 19 | 18 | 18 | 15 | 13 | 13 | 13 | 14 | 14 | 13 | 13 | 14 | 14 | 13 | 14 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Profit Before Tax | 86 | 86 | 59 | 184 | 101 | 130 | 80 | 129 | 103 | 110 | 71 | 124 | 105 | 30 | 64 |
| Tax | 23 | 23 | 15 | 43 | 25 | 35 | 20 | 34 | 26 | 29 | 17 | 32 | 27 | 8 | 15 |
| Net Profit | 64 | 63 | 44 | 140 | 76 | 96 | 60 | 95 | 78 | 81 | 55 | 92 | 77 | 22 | 49 |
| EPS | 6.08 | 6.03 | 4.21 | 13.42 | 7.26 | 9.15 | 5.70 | 9.08 | 7.41 | 7.74 | 5.21 | 8.75 | 7.40 | 2.10 | 4.71 |
Concord Biotech Cash Flow Screener - Liquidity Fundamentals
Screen CONCORDBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|
| Operating Activities | 245 | 266 | 246 | 208 | 167 | 155 |
| Investing Activities | -160 | -155 | -158 | -112 | -195 | -114 |
| Financing Activities | -99 | -99 | -85 | -100 | 31 | -43 |
| Net Cash Flow | -14 | 12 | 3 | -5 | 3 | -1 |
Concord Biotech Shareholding Pattern Screener
See Concord Biotech shareholding pattern with promoter, FII, and DII holdings.
Check Concord Biotech promoter holding and ownership changes for CONCORDBIO on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% |
| FII Holding | 7.80% | 9.35% | 9.11% | 8.03% | 7.58% | 6.48% | 7.11% | 8.10% |
| DII Holding | 9.22% | 9.16% | 8.87% | 9.55% | 9.58% | 8.46% | 10.40% | 9.89% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 8.09% | 6.94% | 7.43% | 7.77% | 8.11% | 7.08% | 7.64% | 7.33% |
| Other Holding | 30.81% | 30.47% | 30.51% | 30.56% | 30.64% | 33.90% | 30.76% | 30.61% |
| Shareholder Count | 82,249 | 81,219 | 82,045 | 82,650 | 81,815 | 83,296 | 80,737 | 84,298 |
Concord Biotech Share Dividend Screener - Share Yield Analysis
Check Concord Biotech dividend history with payout and yield data.
View Concord Biotech dividend details including ex-dates and amounts for CONCORDBIO stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹10.70 | 1.05% |
| 2024-March | ₹8.75 | 0.52% |
| 2023-March | ₹6.83 | 0.45% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Concord Biotech Stock Index Membership
See which indices include Concord Biotech stock.
Check CONCORDBIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH
Concord Biotech Market Events Screener - Corporate Actions
Get Concord Biotech corporate actions including splits, bonuses, and buybacks.
Check Concord Biotech stock events that may affect CONCORDBIO share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 10.70 /share | 3.39% | ||
| Annual General Meeting | NA | -2.31% | ||
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 9.87% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 4.87% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | -6.13% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | 6.76% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -0.32% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | 2.08% |
| 2024-06-29 | 2024-06-29 | Annual General Meeting | NA | 6.09% |
| 2024-06-21 | 2024-06-22 | Dividend | ₹ 8.75 /share | 6.79% |
Concord Biotech Competitors Screener - Peer Comparison
Screen CONCORDBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,643 | 40.81 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 179,470 | 74.13 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 149,109 | 65.68 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,682 | 30.09 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,567 | 26.16 | 33,593 | -0.44% | 3,998 | 59.87 |
| Lupin | 104,032 | 19.28 | 27,488 | 19.98% | 5,345 | 46.11 |
| Mankind Pharma | 103,325 | 56.36 | 12,744 | 20.90% | 2,007 | 73.37 |
| Zydus Life Science | 101,801 | 19.85 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,806 | 25.16 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,455 | 79.78 | 6,813 | 21.03% | 884 | 80.26 |
Concord Biotech Company Announcements - News Screener
Screen CONCORDBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-02 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | - |
| 2026-03-27 | Closure of Trading Window | - |
| 2026-02-26 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-11 | Disclosure Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-02-11 | Unaudited Standalone And Consolidated Financial Results For The Third Quarter And Nine Months Ended On December On 31 2025 | - |
| 2026-02-11 | Appointment of Company Secretary and Compliance Officer | - |
| 2026-02-11 | Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Wednesday February 11 2026 | - |
| 2026-02-09 | Clarification Regarding Increase In Volume | - |
| 2026-02-09 | Clarification sought from Concord Biotech Ltd | - |
| 2026-02-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-06 | Board Meeting Intimation for Board Meeting Intimation For Financial Results | - |
| 2026-01-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-26 | Closure of Trading Window | - |